Do Biological Agents be Useful in the Treatment of Amyloidosis Related FMF

Introduction Familial Mediterranean Fever (FMF), is an autosomal recessive disease associated with mutations in the MEFV gene, affecting mostly Mediterranean populations (Armenians, Arabs, Jewsand, Turks). It is characterized by self-limited recurrent attacks of fever and serositis [1]. Since 1972, colchicine is the standard treatment in FMF patients and majority of the patients achieve complete or partial remission together with colchicine therapy [2,3]. The most serious complication of FMF is AA-type amyloidosis, which can result in end-stage renal disease (ESRD) [4]. There is limited data on the treatment of amyloidosis caused by FMF in children. Abstract

[1]  S. Ozen,et al.  Anti-interleukin 1 treatment in secondary renal amyloidosis associated with autoinflammatory diseases , 2015, Pediatric Rheumatology Online Journal.

[2]  M. Eki̇m,et al.  Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis , 2016, Clinical Rheumatology.

[3]  S. Akar,et al.  Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever , 2014, Inflammation.

[4]  P. Portincasa,et al.  Novel Therapeutics for the Treatment of Familial Mediterranean Fever: From Colchicine to Biologics , 2013, Clinical pharmacology and therapeutics.

[5]  M. Eki̇m,et al.  Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up , 2012, Clinical Rheumatology.

[6]  J. Peltier,et al.  Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Ş. Erten,et al.  Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF , 2012, Rheumatology International.

[8]  O. Akgul,et al.  Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature , 2011, Modern rheumatology.

[9]  I. Mitroulis,et al.  Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. , 2010, European journal of internal medicine.

[10]  J. Frenkel,et al.  Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra , 2007, Annals of the rheumatic diseases.

[11]  M. Eki̇m,et al.  Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. , 2006, Rheumatology.

[12]  A. Bakkaloğlu,et al.  Familial Mediterranean Fever (FMF) in Turkey: Results of a Nationwide Multicenter Study , 2005, Medicine.

[13]  L. Memış,et al.  Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever , 2003, Pediatric Nephrology.

[14]  D. Cattan,et al.  [Familial Mediterranean fever]. , 2002, La Revue du praticien.

[15]  S. Goldfinger.  Colchicine for familial Mediterranean fever. , 1972, The New England journal of medicine.